Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
Anti-Cancer Drugs, 07/02/09
Minisini AM et al. - In a trial to retrospectively analyze the incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses in 145 breast cancer pts, it was determined that recovery of menses after chemotherapy-induced amenorrhea occurs more probably in younger women, with no pregnancies and receiving taxanes.
Methods- Incidence of amenorrhea after adjuvant chemotherapy and subsequent recovery of menses were analyzed in 145 breast cancer pts.
- Age, smoking, alcohol consumption, body mass index, chemotherapy regimen, previous hormonal therapies, and previous childbearing were analyzed as potential predictive factors of ovarian function recovery.
- Median age was 42 yrs at the beginning of adjuvant chemotherapy with 30.3% of pts below 40 yrs of age.
- The majority (87.6%) of pts received anthracycline-based chemotherapy, 35.2% of pts received a cyclophosphamide-methotrexate-5-fluorouracil regimen, and 42.8% received a taxane.
- Incidence of chemotherapy-induced amenorrhea was 80, and 35.3% of these pts resumed menses after a median of 8 mos.
- Younger age (<40 yrs) and taxane-based chemotherapy were associated with increased probability of recovery of menses after chemotherapy-induced amenorrhea.
- Cyclophosphamide-methotrexate-5-fluorouracil-based chemotherapy and previous childbearing were associated with an increased probability of permanent chemotherapy-induced amenorrhea.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Pomegranate fruit extract impairs invasion and motility in human breast cancer
Integrative Cancer Therapies , 10/12/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer
Cochrane Reviews, 10/09/09
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Annals of Internal Medicine, 10/20/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


